You may feel well through perimenopause and still be losing bone faster than you realize. That is why the question of when to test bone density during menopause matters: the biological change often begins years before routine screening is typically discussed.
A fracture is the event people notice. Bone loss is the quieter process that precedes it. Menopause is not a reason to assume something is wrong with your bones, but it is a meaningful point to understand what information you have, what you do not, and whether your risk profile calls for earlier assessment.
When to test bone density during menopause
Estrogen helps regulate the normal cycle of bone remodeling. Throughout life, bone tissue is continually broken down and rebuilt. As estrogen levels become more variable in perimenopause and then decline after menopause, breakdown can outpace rebuilding. The result can be a relatively rapid loss of bone mineral density, especially around the spine and hip.
The timing is not identical for everyone. Some people enter menopause with high peak bone mass and few additional risk factors. Others begin the transition after years of factors that affect skeletal health, such as low body weight, smoking history, thyroid conditions, inflammatory disease, certain medications, or a parent who had a hip fracture.
Perimenopause is often the right time to ask the question
Perimenopause is the transition leading up to the final menstrual period. Cycles may become irregular, but bone metabolism may already be changing. A baseline assessment during this period can be useful when there are risk factors, a history of low-trauma fracture, or a major upcoming health decision that could affect bone.
A baseline does not predict your future with certainty. It gives you a starting point. Without one, a later measurement can identify where you are, but it cannot show how quickly the change occurred or what your bone status was before the menopausal transition.
The first years after menopause deserve attention
Bone loss commonly accelerates in the years surrounding the final menstrual period. This is the window when an earlier assessment may be most informative for someone with added risk, particularly if menopause occurs before age 45 or follows ovary removal or cancer treatment that affects estrogen production.
Routine screening recommendations are not the same as an individualized decision to assess bone health. In the United States, major guidelines generally recommend osteoporosis screening for women age 65 and older, as well as younger postmenopausal women with increased risk. That age-based threshold is useful for population screening. It does not mean bone biology waits until 65 to change.
Screening guidelines are a floor, not a full picture
For a healthy person in early perimenopause with no fracture history or meaningful risk factors, immediate testing may not change clinical decisions. For someone with several risk factors, waiting solely because they are younger than the routine screening age can leave a long period without objective information.
The distinction is worth making. Screening guidelines answer, “Who should be routinely screened so fewer people are missed?” A personal bone-health assessment asks, “What information would clarify this person’s risk now?” Those are related questions, but they are not interchangeable.
A clinician may weigh age, menopausal stage, family history, body size, prior fractures, medication history, health conditions, and fall risk. The purpose is not to turn menopause into a diagnosis. It is to recognize that the transition changes the context for your bones.
Density matters, but it does not tell the whole fragility story
A standard bone density test measures bone mineral density, usually at the lumbar spine and hip. The result is often reported as a T-score, which compares your density with that of a healthy young adult reference population. A T-score can identify osteoporosis and osteopenia, and it remains central to bone-health evaluation.
But density answers one question: how much mineralized bone is present? It does not fully answer whether the bone is showing signs associated with greater fragility.
Consider two people with similar density at the hip. Their density scores may suggest a similar amount of mineralized bone. Yet their fracture risk may not be the same, because fragility is influenced by more than the quantity of mineralized bone. This is one reason a reassuring density result should be interpreted alongside the rest of a person’s health picture rather than treated as the entire answer.
REMS, or radiofrequency echographic multi-spectrometry, measures bone mineral density at the lumbar spine and proximal femur using radiation-free ultrasound. It also analyzes the reflected ultrasound signals to derive an independent Fragility Score. The score reflects signal patterns associated with skeletal fragility that density alone does not capture. Density and Fragility Score are then considered together to estimate five-year fracture risk.
That creates a more complete conversation: How much bone do you have? Is the ultrasound signal showing signs associated with greater fragility? And what does the combination mean for near-term fracture risk?
It is also useful for monitoring because precision affects what a change on a report means. Small shifts can reflect normal measurement variation rather than a real biological change. REMS has an intra-operator precision error below 0.5%, compared with the roughly 0.9% to 1.9% often reported for DXA at the spine. Tighter precision can make follow-up measurements more meaningful when a clinician is tracking change over time.
Situations that can justify an earlier conversation
Menopause is one factor, not the whole risk picture. Earlier bone assessment is particularly reasonable to discuss when menopause overlaps with other known concerns, including:
- A fracture from a fall that would not ordinarily be expected to break a bone
- Menopause before age 45, or surgical or treatment-related loss of ovarian function
- Long-term glucocorticoid use, such as prednisone
- A parent with a hip fracture or a personal history of osteoporosis
- Low body weight, substantial unintentional weight loss, or rapid weight loss
- Conditions associated with altered bone health, including rheumatoid arthritis, celiac disease, and chronic kidney disease
Type 2 diabetes deserves special attention because it exposes a limitation of density-only thinking. People with type 2 diabetes can have normal or even higher bone mineral density while still experiencing higher fracture risk. The reasons are complex and may include changes in bone material properties and a greater likelihood of falls. The practical point is clear: a normal density score is not always the same thing as low skeletal risk.
Similar questions can arise with GLP-1-associated weight loss, cancer-treatment history, or a planned orthopedic procedure. In each case, bone information may help frame a more informed discussion with the clinician involved in your care.
What to bring to the conversation
If you are deciding whether this is the right time to test, gather the details that make your risk picture clearer: the age of your final menstrual period if it has occurred, fracture history, family history, medication use, major weight changes, and relevant diagnoses. These details give context to any scan result.
It also helps to ask what the test can measure and what it cannot. Bone density is meaningful, but it is not a direct measurement of every aspect of bone strength. A Fragility Score adds independent information from the ultrasound signal, but it is still one part of a clinical assessment. The most useful report is one you can understand, follow over time, and share with your physician.
Menopause is a transition, not a deadline. The value of testing is not in chasing a number. It is in making an invisible process understandable early enough that your future bone decisions are based on information rather than surprise.